Drug Trial Radar · NCT06413095
PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS
Last checked: Nov 19, 2026Latest source record: May 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Jun 1, 2022
Primary completion
Jun 22, 2023
Study completion Jun 22, 2023
Sponsor
- Lead sponsor
- Presage BiosciencesIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- May 14, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label, Phase 0 substudy designed to evaluate the ability of pembrolizumab, alone and in combination with MK-0482 or MK-4830, to elicit pharmacodynamic changes suggestive of antitumor immune activation within the native tumor microenvironment (TME) following intratumoral microdosing via the CIVO device in patients with surface accessible Head and Neck Squamous Cell Carcinoma (HNSCC) or Soft Tissue Sarcoma (STS) lesion(s) who are scheduled for tumor and/or regional node dissection as part of their standard treatment.
Conditions
- Head and Neck Squamous Cell Carcinoma
- Soft Tissue Sarcoma
Interventions
PembrolizumabBiological
Intratumoral microdose injection by the CIVO device.
MK-0482 + PembrolizumabCombination product
Intratumoral microdose injection by the CIVO device.
MK-4830 + PembrolizumabCombination product
Intratumoral microdose injection by the CIVO device.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Quantification of Immune Cell Biomarkers by Immunohistochemistry (IHC), In Situ Hybridization (ISH), and/or Spatial Biology PlatformsTime frame: 2 to 4 days after microdose injection
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
UC Davis
Sacramento, California
Emory Winship Cancer Institute
Atlanta, Georgia
LSU Health Sciences Center - Shreveport
Shreveport, Louisiana
Montefiore Medical Center
The Bronx, New York
University of North Carolina
Chapel Hill, North Carolina
UC Health
Cincinnati, Ohio
Oregon Health & Science University (OHSU)
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
Sarah Cannon Medical Center
Charleston, South Carolina
UT Health Houston
Houston, Texas
University of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.